Development of the composition and technology of capsules from of Betula Pubescens Ehrh. extracts

Aim. To develop the technology of a medicinal product in capsule form with mild diuretic activity based on dry extract of birch buds.

Materials and methods. During experimental research, a technology for obtaining dry extract from birch buds using 70% ethanol was developed. A material balance was calculated, and a technological and equipment flow chart was created. After optimizing the extraction conditions, the composition of a solid dosage form (capsule) was developed and prepared using a capsule-filling machine.

Results and discussion. Optimal extraction conditions were identified: raw material to extractant ratio – 1:1; solvent – 70% ethanol; temperature – 45-50 °C. The obtained dry extract was incorporated into the capsule formulation as follows: 0.300 g of dry birch bud extract, 0.195 g of potato starch, 0.003 g of Aerosil A-380, and 0.002 g of calcium stearate. All samples were studied in accordance with the requirements of the State Pharmacopoeia of the Republic of Kazakhstan.

Conclusions. A technology was developed for obtaining a dry extract from birch buds and a capsuleform medicinal product based on it, substantiated by the results of experimental research.

1. Vinogradova N.G., Berestovskaja V.S., Blankova Z.N., Vavilova T.V., Gomyranova N.V., Masenko V.P., Mareev V.Ju., Skvorcov A.A., Sorokina N.A., Tereshhenko S.N. Laboratornye aspekty ispol’zovanija rezul’tatov immunohimicheskogo opredelenija koncentracii NT-proBNP pri vedenii pacientov s hronicheskoj serdechnoj nedostatochnost’ju: podderzhka prinjatija klinicheskih reshenij. Kardiologija. 2024; 64 (8): 68-78. https://doi.org/10.18087/cardio.2024.8.n2720

2. Zhankalova Z.M., Nogaeva M.G., Orazbaeva M.M., Kushimbaeva K.K., Hajbullina G.M., Esirkepova A.Zh., Gabdullina G.H. Sozylmaly zhүrek zhetkіlіksіzdіgі bar nauқastardaғy psihojemocionaldy kүj. Nauka i zdravoohranenie. 2023; 25 (5): 221-231. https://doi.org/10.34689/SH.2023.25.5.028

3. Endrighi R., Waters A.J., Gottlieb S.S., Harris K.M., Wawrzyniak A.J., Bekkouche N.S., Li Y., Kop W.J., Krantz D.S. Psychological stress and shortterm hospitalisations or death in patients with heart failure. Heart. 2016; 102 (22): 1820-1825. https://doi.org/10.1136/heartjnl-2015-309154

4. Polzik G.B., Kapsultanova D.A., Shvedkova T.A., Bezina E.M., Eshmuhambetova M.A., Isagalieva D.T., Sardarova G.O., Utina G.A., & Jusenova A.G. Sozylmaly arterijalyқ gipertenzijanyң klinikalyқ zhaғdajy. Vestnik Kazahskogo Nacional’nogo medicinskogo universiteta. 2016; 3: 6-9.

5. Bekbosynova M.S., Ivanova-Razumova T.V., Dzhetybaeva S.K., Oralbekova Zh.O. Kardiologicheskaja sluzhba Kazahstana segodnja: ostryj koronarnyj sindrom, hronicheskaja serdechnaja nedostatochnost’, ateroskleroz. Kardiologija. 2024; 64 (1): 34-36. https://doi.org/10.18087/cardio.2024.1.n2580

6. Kosherbaeva L., Samambaeva A., Boquete Yolanda Pena, Imamatdinova A. Metodologija rascheta predotvratimoj smertnosti na primere serdechno-sosudistyh zabolevanij v Kazahstane. Nauka i Zdravoohranenie. 2022; 4 (24): 101-107. https://doi.org/10.34689/SH.2022.24.4.013

7. Mamas M.A., Sperrin M., Watson M.C., Coutts A., Wilde K., Burton C., Kadam U.T., Kwok C.S., Clark A.B., Murchie P., Buchan I., Hannaford P.C., Myint PK. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur. J. Heart. Fail. 2017; 19 (9): 1095-1104. https://doi.org/10.1002/ejhf.822

8. Vaduganathan M., Claggett B.L., Jhund P.S., Cunningham J.W., Ferreira J.P., Zannad F., Packer M., Fonarow G.C., McMurray J.J.V., Solomon S.D., Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. The Lancet. 2020; 396 (10244): 121-128. https://doi.org/10.1016/S0140-6736(20)30748-0

9. Cowie M.R., Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat. Rev. Cardiol. 2020; 17 (12): 761-772. https://doi.org/10.1038/s41569-020-0406-8

10. Kuznecova O.Ju. Obzor sovremennyh preparatov s biologicheski aktivnymi kompozicijami berezovogo griba chaga. Razrabotka i registracija lekarstvennyh sredstv. 2016; 1: 128-141.

11. Mashentseva A.A., Dehaen W., Seitembetov T.S., Seitembetova A.J. Comparison of the antioxidant activity of the different Betula pendula Roth. extracts from northern Kazakhstan. Journal of Phytology. 2011; 3 (1): 18-25.

12. Morozova I.V., Chernobrovkina N.P., Pchjolkin V.P. Frakcionnyj i zhirnokislotnyj sostav lipidov fragmentov pochek po fazam raspuskanija u rastenij roda Betula L. Fiziologija rastenij. 2024; 71 (6): 723-734. https://doi.org/10.31857/S0015330324060059

13. EFSA Panel on Plant Health (PLH); Civera A.V., Baptista P., Berlin A., Chatzivassiliou E., Cubero J., Cunniffe N., de la Peña E., Desneux N., Di Serio F., Filipiak A., Hasiów-Jaroszewska B., Jactel H., Landa B.B., Maistrello L., Makowski D., Milonas P., Papadopulos N.T., Potting R., Susi H., Van Der Gaag D.J., Battisti A., Mas H., Rigling D., Faccoli M., Mikulová A., Stergulc F., Christoph E., MosbachSchulz O., Streissl F., Gonthier P. Commodity risk assessment of Betula pendula and Betula pubescens plants from the UK. EFSA J. 2024; 22 (11): e9051. https://doi.org/10.2903/j.efsa.2024.9051

14. Harr L., Esper J., Kirchhefer J.A. et al. Growth response of Betula pubescens Ehrh. to varying disturbance factors in northern Norway. Trees. 2021; 35: 421-431. https://doi.org/10.1007/s00468-020-02043-1

15. Paniagua-Zambrana N. Y. et al. Betula pendula Roth Betula pubescens Ehrh. Betulacae. Ethnobotany of the Mountain Regions of Eastern Europe: Carpathians. Cham: Springer International Publishing; 2024: 1-16. https://doi.org/10.1007/978-3-031-87802-2_50

16. Isakov I. Y. The effect of a single inbreeding on the growth and development of fast-growing tree species, Betula pendula and Betula pubescens. IOP Conference Series: Earth and Environmental Science. 2021; 875 (1): 012014. https://doi.org/10.1088/1755-1315/875/1/012014

17. Kachalina T. V., Malysheva N.A., Semkina O.A., Dzhavahjan M.A. Razrabotka sostava i tehnologii kapsul, soderzhashhih vinograda kul’turnogo list’ev krasnyh jekstrakt suhoj. Voprosy biologicheskoj, medicinskoj i farmacevticheskoj himii. 2020; 23 (8): 19-25.

18. Abdurahimov A. H., Jergasheva Z. A., Usmanov H. A. Primenenie jekzotoksina holernogo vibriona dlja lechenija hronicheskoj pochechnoj nedostatochnosti. Health journal. 2020; 1 (5): 111-113. https://doi.org/10.24411/2181-0443/2020-10023

19. Kalashnikova V. N., Al’djakov A. V. Diagnostika i lechenie hronicheskoj pochechnoj nedostatochnosti u koshek. Studencheskaja naukapervyj shag v akademicheskuju nauku. M.; 2021: 242-245.

20. Poljakov D.S., Fomin I.V., Belenkov Ju.N., Mareev V.Ju., Ageev F.T., Artem’eva E.G., Badin Ju.V., Bakulina E.V., Vinogradova N.G., Galjavich A.S., Ionova T.S., Kamalov G.M., Kechedzhieva S.G., Koziolova N.A., Malenkova V.Ju., Mal’chikova S.V., Mareev Ju.V., Smirnova E.A., Tarlovskaja E.I., Shherbinina E.V., Jakushin S.S. Hronicheskaja serdechnaja nedostatochnost’ v Rossijskoj Federacii: chto izmenilos’ za 20 let nabljudenija? Rezul’taty issledovanija JePOHA-HSN. Kardiologija. 2021; 61 (4): 4-14. https://doi.org/10.18087/cardio.2021.4.n1628

21. Bashirov A.U. Jepidemiologija hronicheskoj serdechnoj nedostatochnosti v Kazahstane i drugih stranah. Ul’janovskij mediko-biologicheskij zhurnal. 2024; 3: 17-27. https://doi.org/10.34014/2227-1848-2024-3-17-27

22. Usmanova U.I., Huzhamberdiev M.A., Mirsajdullaev M.M. Nejrogormony i citokiny pri serdechnoj nedostatochnosti. I Evrazijskij kongress kardiologov. I Nacional’nyj kongress kardiologov Kazahstana. Astana; 2009: 78-78.

23. Berkinbaev S.F., Dzhunusbekova G.A., Isabekova A.H. Klinicheskaja jeffektivnost’ petlevogo diuretika torasemida v lechenii bol’nyh hronicheskoj serdechnoj nedostatochnost’ju. Rezul’taty kazahstanskogo mnogocentrovogo issledovanija «POJeT». Racional’naja Farmakoterapija v Kardiologii. 2014; 10 (5): 495-499. https://doi.org/10.20996/1819-6446-2014-10-5-495-499

24. Sambukova T.V., Ovchinnikov B.V., Ganapol’skij V.P., Jatmanov A.N., Shabanov P.D. Perspektivy ispol’zovanija fitopreparatov v sovremennoj farmakologii. Obzory po klinicheskoj farmakologii i lekarstvennoj terapii. 2017; 15 (2): 55-62.

25. Safonova N.V., Trofimova E.O. Obzor rossijskogo rynka rastitel’nyh preparatov. Remedium. Zhurnal o rossijskom rynke lekarstv i medicinskoj tehnike. 2021; 3: 11-22.

26. Gosudarstvennaja farmakopeja Respubliki Kazahstan. T. 1. Almaty: Izdatel’skij dom «Zhibek zholy»; 2008: 592.

27. Gosudarstvennaja farmakopeja Respubliki Kazahstan. T. 2. Almaty: Izdatel’skij dom «Zhibek zholy»; 2009: 804.

28. Gosudarstvennaja farmakopeja Respubliki Kazahstan. T. 1. Almaty: Izdatel’skij dom «Zhibek zholy»; 2014: 872.

29. Omarova R.A. Nekotorye aspekty hronicheskoj serdechnoj nedostatochnosti. Kardiovaskuljarnaja terapija i profilaktika. 2019; 18 (1): 117-118.

30. Dzhunusbekova G.A., Tundybaeva M.K., Leonovich T.N. Problema diagnostiki fibrilljacii predserdij v respublike Kazahstan. Konsensus soveta jekspertov. Science & Healthcare. 2022; 24 (2): 240-248.